The severe phenotype of leukocyte adhesion deficiency (LAD) is a congenital disorder of the leukocyte function that is usually fatal in the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for this disease. Hematopoietic stem cell transplantation using a reduced intensity-conditioning (RIC) regimen might be useful for LAD because the HSCT with RIC is presumed to be sufficient for the establishment of a donor-derived immune reconstitution with less regimen-related toxicity, and patients treated by this modality usually have comorbidity. We herein describe the first case to undergo an unrelated donor bone marrow transplantation with RIC in a patient demonstrating LAD.
Patients with leukocyte adhesion deficiency type I (LAD-I) tend to suffer recurrent and life-threatening bacterial infections because of a lack of the leukocyte adherence and migration caused by a mutation in the gene encoding the beta-2 integrin, cluster of differentiation (CD)18, which is located on the long arm of chromosome 21. Such a mutation results in the absence or a reduced membrane expression of leukocyte-associated integrins: lymphocyte function-associated antigen 1 (CD11a/CD18), Mac-1 (CD11b/CD18) and p150-95 (CD11c/CD18). 1 In patients with a severe phenotype, leukocytes are expressed at o1% of the normal levels of CD18, and at o10% of the normal levels in the moderate phenotype. 2 Patients with the severe form of LAD-I usually die of infection before 2 years of age, while the moderate phenotype is associated with a more prolonged survival, although the quality of life is poor and death eventually occurs in most cases. 3 Allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as the only curative option for LAD during childhood, especially for severe phenotype. We herein report the first case to undergo an unrelated bone marrow transplantation (BMT) with a reduced intensity conditioning in LAD.
The patient was the first-born child at full term by an emergency cesarean section because of bradytocia. She presented with omphalitis, pneumonia, laryngitis and tympanitis with marked leukocytosis, and thus was admitted to the hospital at 4 months of age. The leukocyte CD11/CD18 expression was less than normal level, and she was thus diagnosed to have LAD.
At 4 years of age, sulfamethoxazole/trimethoprim was started for the prophylaxis of recurrent bacterial infections.
Thereafter, the occurrence of infectious episodes decreased markedly; however, she still had to be admitted several times because of recurrent abscesses, pneumonia, cellulitis, gingivitis, laryngitis and erysipelas.
At 23 . In a flow-cytometric analysis, 1.6% of her peripheral blood white cells expressed b-2 integrin pretransplant. Since pneumonia with gingivitis and Pseudomonas aeruginosa had been isolated from her sputum before transplantation, antibiotics were administered intravenously since the initiation of the conditioning regimen. The donor and recipient were serologically matched at all four human leukocyte antigen (HLA)-A and -B loci (but they were molecularly mismatched at one B locus) and molecularly matched at the DRB1 loci. The patient received 2.78 Â 10 8 /kg and 1.53 Â 10 6 /kg of total nucleated cells and CD34-positive cells, respectively. The prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus and short-term methotrexate. Granulocyte colony-stimulating factor was administered on days 7-21. Prompt hematopoietic engraftment was observed with an absolute neutrophil count of 0.5 Â 10 9 /l by day 20. A flow-cytometric analysis on day 39 revealed a normal antigen expression of CD11/CD18 in the peripheral blood, and complete chimera was demonstrated by fluorescence in situ hybridization of the sex chromosome because the donor was male.
The post-transplant course was complicated by a moderate degree of oral mucositis, invasive pulmonary aspergillosis, acute renal failure induced by the nephrotoxic agents, cytomegalovirus infection and hemorrhagic cystitis. Acute GVHD of grade IV that occurred on day 39 did not respond to intensive immunosuppressive therapy and the patient thereafter died of invasive pulmonary aspergillosis with severe acute GVHD on day 55.
Hematopoietic stem cell transplantation is the only curative therapy available for patients with LAD-I. Since 1977, several reports have been published on conventional bone marrow transplantation for LAD. [2] [3] [4] The aim of myeloablative conditioning for LAD is to achieve complete donor chimerism; however, toxicities related to the conditioning regimen remain a major limitation in the application of conventional conditioning regimens for patients with comorbidity. Reduced-intensity conditioning (RIC) regimens are designed to produce durable donor engraftment with less regimen-related toxicity. Hematopoietic stem cell transplantation with RIC regimens have been reported to be successfully performed in patients contraindicated for conventional HSCT because of their age and/or comorbidity, in addition to the reported effectiveness of the HSCT with RIC to several congenital immunodeficiencies. A nonmyeloablative conditioning regimen with busulfan alone may thus be able to reverse the disease phenotype in canine leukocyte adhesion deficiency (CLAD). 5 Canine leukocyte adhesion deficiency dogs received 10 mg/kg of busulfan intravenously before the infusion of matched littermate bone marrow. They all achieved mixed chimeras and resulted in no more infectious episodes, thus indicating that the RIC regimen could potentially reverse the disease phenotype in CLAD. Our case was successfully engrafted and her bone marrow showed complete chimera. On the other hand, failure of engraftmentassociated autologous marrow recovery has been observed in several cases of BMT in children, even from genotypically identical donors in LAD patients. It is possible that there is a major age effect, since virtually all other patients were transplanted during childhood. As there has so far been no report regarding the RIC for pediatric recipients with LAD, RIC for BMT in LAD needs further exploration.
Our patient developed acute GVHD of grade IV. Thomas et al.
3 noted a trend towards a high rate of both acute and chronic GVHD in their LAD patients, even in those receiving BMT from an HLA-identical sibling donor. They could not give any obvious explanation for the higher frequency and greater severity of GVHD in LAD patients. Moreover, the rates of acute GVHD still remain high in most studies, and acute GVHD of grade III or IV is still more frequently observed after RIC, thus suggesting the induction of a cytokine storm in low-level post-conditioning. 6 This is the first report of an unrelated BMT conditioned with RIC in LAD. A successful engraftment detected the expression of CD11/CD18; however, severe acute GVHD occurred and the recipient died of invasive pulmonary aspergillosis. Prospective studies including the selection of the conditioning regimen are thus needed to elucidate the role of HSCT with RIC in LAD. 
